Taro Pharmaceutical Industries Ltd.

Overview

Taro Pharmaceutical Industries Ltd. is a research-based international pharmaceutical company that develops, manufactures, and markets affordable prescription and over-the-counter pharmaceutical products. It operates primarily in the U.S., Canada, and Israel, with a strong focus on dermatology, topical, and oral medications.

Core services & business areas

Therapeutic areas

Active pharmaceutical ingredients supplied

Substances Taro Pharmaceutical Industries Ltd. is evidenced to supply (US FDA Drug Master File or EU CEP). Open any ingredient to see its full supplier landscape, CAS number and patent status.

API / Drug Master Files

Taro Pharmaceutical Industries Ltd. holds 63 active (64 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• TAPINAROFActive2026-01-15
• TIRBANIBULINActive2024-08-01
• IMIQUIMOD, USP (NEW ROS)Active2024-03-31
• TRIFAROTENEActive2023-03-31
• DOCOSANOLActive2019-03-18
• TICAGRELORActive2018-03-30
• TAVABOROLEActive2018-03-26
• LULICONAZOLEActive2017-03-30
• TERBINAFINE HYDROCHLORIDE USPActive2017-03-23
• PERAMPANEL 3/4 HYDRATE, MICRONIZEDActive2016-06-30
• DAPSONE USPActive2016-03-31
• AZELAIC ACID, MICRONIZEDActive2015-12-01
• DEFERIPRONEActive2015-03-30
• RIVAROXABAN USP MICRONIZEDActive2015-03-06
• AZITHROMYCIN MONOHYDRATE USPActive2015-03-02

Showing 15 of 64 Drug Master Files.

FDA compliance signals